Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Damora TherapeuticsDMRA -5.63%28 3-Year EPS without NRI Growth Rate is 59.60% as of Jun. 2026, which is 99% above its 10-year median of 30.00. GuruFocus rates DMRA with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,160 Biotechnology companies, Damora Therapeutics ranks better than 89.4% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 59.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 48.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Damora Therapeutics was 59.60% per year. The lowest was 6.30% per year. And the median was 30.00% per year.
Damora Therapeutics (NAS:DMRA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Damora Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
DMRA vs SLBT, BCAX, TYRA: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Damora Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Damora Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Damora Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Damora Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Damora Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 59.60% mean?
Damora Therapeutics (DMRA) has a 3-Year EPS without NRI Growth Rate of 59.60% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Damora Therapeutics and its competitors. This is 99% above median its historical median of 30.00. Over the past decade, Damora Therapeutics' 3-Year EPS without NRI Growth Rate has ranged from 6.30 to 59.60. According to the industry distribution chart, Damora Therapeutics ranks #123 out of 1160 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Damora Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Damora Therapeutics' current 3-Year EPS without NRI Growth Rate of 59.60% is 99% above median its 10-year median of 30.00. Over the past 10 years, this metric has ranged from a low of 6.30 to a high of 59.60. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Damora Therapeutics' value of 59.60% is 267.9% above this industry median. Based on the distribution chart, Damora Therapeutics ranks #123 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Damora Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Damora Therapeutics' 3-Year EPS without NRI Growth Rate compare to SLBT and BCAX?
According to the Biotechnology industry distribution chart, Damora Therapeutics ranks #123 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Damora Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Damora Therapeutics' value of 59.60% is 267.9% above this benchmark. Historically, Damora Therapeutics' own 3-Year EPS without NRI Growth Rate has ranged from 6.30 to 59.60 over the past decade. While the company's 10-year median is 30.00 vs. the industry median of 16.20, Damora Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Damora Therapeutics's current 3-Year EPS without NRI Growth Rate of 59.60% is 267.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Damora Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Damora Therapeutics's current 3-Year EPS without NRI Growth Rate is 59.60%, which is 99% above median its own 10-year median of 30.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Damora Therapeutics stock overvalued right now?
Damora Therapeutics (DMRA) has a current 3-Year EPS without NRI Growth Rate of 59.60%. The current 3-Year EPS without NRI Growth Rate is 59.60%, which is 99% above median its 10-year median of 30.00 and 267.9% above the Biotechnology industry median of 16.20. Damora Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Damora Therapeutics (DMRA), the current 3-Year EPS without NRI Growth Rate is 59.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
28GF Score
Get the complete analysis for DMRA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMRA has been successfully added to your 
